Theratechnologies (NASDAQ:THTX) Announces Earnings Results

Theratechnologies (NASDAQ:THTX) announced its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03), MarketWatch Earnings reports. Theratechnologies had a negative net margin of 28.20% and a negative return on equity of 81.13%.

Shares of NASDAQ THTX opened at $2.27 on Friday. The company has a debt-to-equity ratio of 3.81, a quick ratio of 1.26 and a current ratio of 1.92. The company has a market cap of $174.82 million, a P/E ratio of -9.46 and a beta of 1.46. The firm’s fifty day moving average is $2.38 and its two-hundred day moving average is $2.23. Theratechnologies has a 52-week low of $1.33 and a 52-week high of $4.20.

A number of analysts recently commented on the company. Zacks Investment Research raised Theratechnologies from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Mackie reissued a “buy” rating and issued a $4.50 price target on shares of Theratechnologies in a report on Friday. Echelon Wealth Partners reaffirmed a “buy” rating and issued a $11.00 target price on shares of Theratechnologies in a research note on Wednesday, July 8th. Canaccord Genuity reiterated a “buy” rating on shares of Theratechnologies in a report on Monday, July 13th. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $2.00 price target on shares of Theratechnologies in a report on Monday, July 20th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.15.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients.

Further Reading: Technical Analysis

Earnings History for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.